Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • HOME
  • ABOUT US
  • POLICY HUB
  • OUR VALUES
  • OUR SERVICES
  • PRIVACY POLICY
  • CONTACT US

Insight, China's Pharmaceutical Industry Fineline Info & Tech is a comprehensive global pharmaceutical database that spans the entire product lifecycle. Its mission is to equip professionals and executives across all sectors of the life sciences industry with a standardized data language, offering a holistic view of the Chinese pharmaceutical competitive landscape. Flcube.com furnishes critical data essential for informed decision-making, drawing on global industry news, policy insights, competitive intelligence, and advanced analytical tools.

Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Company Drug PIC

GSK’s Shingrix Wins Japan Approval for Prefilled Syringe Presentation – Recombinant Zoster Vaccine Gains Administration Flexibility

Fineline Cube Sep 11, 2026
Company Drug PIC

Hengrui’s Hetrombopag Wins China Approval for CTIT and Pediatric ITP – Oral TPO‑RA Expands Across Thrombocytopenia Indications

Fineline Cube Sep 11, 2026
Company Drug PIC

Roche’s Enspryng Granted FDA Priority Review for MOGAD – First IL‑6 Inhibitor Poised to Expand Beyond NMOSD

Fineline Cube Sep 11, 2026
Company Deals PIC

Boji Medical and Zhejiang Maiyata Sign Strategic Partnership – Leading China CRO Joins Microbiome Innovator to Advance Live Biotherapeutic Products

Fineline Cube Sep 11, 2026
Company Drug PIC

Allergan Aesthetics’ JUVÉDERM VOLBELLA Wins NMPA Approval for Infraorbital Hollowing – Hyaluronic Acid Filler Expands China Label Beyond Lips

Fineline Cube Sep 11, 2026
Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Fineline Cube Sep 11, 2026
Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Fineline Cube Sep 11, 2026
Company Deals

EC Healthcare Partners with Jiangxi Rimag Group to Expand Medical Imaging Services

Fineline Cube Nov 22, 2023

China-based EC Healthcare (HKG: 2138) has entered into a partnership with Jiangxi Rimag Group Co.,...

Company Deals

Dizal Pharmaceutical and Wuxi Gaofa Investment to Establish Joint Venture for Auto-Immune Disease Treatments

Fineline Cube Nov 22, 2023

China-based AstraZeneca (AZ, NASDAQ: AZN) spin-out, Dizal Pharmaceutical Co., Ltd (SHA: 688192), has entered into...

Company Deals

BeiGene Ltd Strikes Exclusive Global License Deal with Ensem Therapeutics for CDK2 Inhibitor

Fineline Cube Nov 22, 2023

China-based biopharmaceutical company BeiGene Ltd (NASDAQ: BGNE; HKG: 6160; SHA: 688235) has announced a licensing...

Company Drug

Fosun Pharmaceutical’s FCN-437c filing Accepted for Review by China’s NMPA

Fineline Cube Nov 22, 2023

Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has announced that the National...

Company Deals

XtalPi Inc. and Singapore’s EDDC Broaden Collaboration in AI-Driven Drug Discovery

Fineline Cube Nov 22, 2023

Sino-US artificial intelligence (AI) firm XtalPi (QuantumPharm, HKG: 2228) has entered into a memorandum of...

Company

Merck KGaA Completes Second Phase of Biologics Testing Center Expansion in China

Fineline Cube Nov 22, 2023

Germany’s major life science company, Merck KGaA (ETR: MRK), has announced the completion of the...

Company

Belgium Bans Ozempic for Weight Loss as Global Shortage Persists

Fineline Cube Nov 21, 2023

Belgium has issued a royal decree prohibiting the use of Novo Nordisk’s (NYSE: NVO) diabetes...

Company Deals

Asia Regenerative Medicine Secures Pre-Series A Financing for Bioartificial Organ Development

Fineline Cube Nov 21, 2023

Shenzhen-based bioartificial organ developer, Asia Regenerative Medicine, has reportedly raised tens of millions of renminbi...

Company Drug

CSPC Pharmaceutical’s Glumetinib Earns Breakthrough Therapy Designation in China

Fineline Cube Nov 21, 2023

Glumetinib, a MET targeted tyrosine kinase inhibitor (TKI) co-developed by CSPC Pharmaceutical Group Ltd (HKG:...

Company Medical Device

AstraZeneca Launches Evinova to Enhance Global Clinical Development with Digital Health Solutions

Fineline Cube Nov 21, 2023

UK-based AstraZeneca (AZ; NASDAQ: AZN) has launched Evinova, a digital health solutions provider, with the...

Company Drug

BMS and 2seventy Bio’s Abecma Faces FDA Review Extension

Fineline Cube Nov 21, 2023

The US Food and Drug Administration (FDA) has postponed the target action date for Bristol...

Company Deals

Suzhou Porton Biologics Partners with Asclepius Technology for NK Cell Project

Fineline Cube Nov 21, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Suzhou Porton Biologics Ltd has entered into a...

Company

Shanghai Pharmaceuticals’ Chairman Zhou Jun Resigns Amid Investigation

Fineline Cube Nov 21, 2023

Shanghai Pharmaceuticals (SPH; HKG: 2607; SHA: 601607), a leading Chinese pharmaceutical distribution company, has announced...

Company Deals

VIVA Biotech Holdings Secures Nearly USD 210 Million in Financing Round

Fineline Cube Nov 21, 2023

China-based Contract Research Organization (CRO) VIVA Biotech Holdings (HKG: 1873) has announced the completion of...

Company Drug

Jiangsu Aidea Pharmaceutical’s AINUOVIRINE Receives Priority Review Status from CDE

Fineline Cube Nov 21, 2023

Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a Chinese pharmaceutical company, has announced that its...

Company Drug

Medilink Therapeutics’ YL201 Earns Orphan Drug Designation for Esophageal Cancer

Fineline Cube Nov 21, 2023

Suzhou-based Medilink Therapeutics has announced that it has obtained orphan drug designation (ODD) from the...

Company Deals

Chiesi Farmaceutici Acquires Global Rights to Haisco Pharmaceutical’s HSK31858 for Respiratory Diseases

Fineline Cube Nov 21, 2023

Italy-based Chiesi Farmaceutici S.p.A has announced a licensing agreement with China-based Haisco Pharmaceutical Group Co.,...

Company Deals

Fosun Pharmaceutical’s US Subsidiary Partners with Treehill Partners for Clinical-Stage Investments

Fineline Cube Nov 21, 2023

Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) through its US subsidiary, Fosun Pharma...

Company Deals

Jiangsu Aidea Pharmaceutical Partners with Fidson Healthcare for HIV/AIDS Treatments in Nigeria

Fineline Cube Nov 20, 2023

China-based Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488) has reportedly entered into a strategic cooperation...

Company Deals

GE Healthcare’s Shanghai Innovation Hub Onboards Initial Start-Ups

Fineline Cube Nov 20, 2023

GE Healthcare’s (NASDAQ: GEHC) newly established Shanghai innovation center, dedicated to advancing healthcare projects, has...

Posts pagination

1 … 494 495 496 … 719

Recent updates

  • Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption
  • BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis
  • Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China
  • China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories
  • Ocumension’s OT‑301 NDA Accepted by China’s CDE – Dual‑Mechanism Glaucoma Therapy Advances Toward Approval in Open‑Angle Glaucoma and Ocular Hypertension
business cooperation with fineline tech

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • PIC
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Hainan Boao Lecheng Pilot Zone Issues Exit Mechanism Rules for Clinical Translation of New Biomedical Technologies – Full‑Process Framework for Suspension, Exit and Resumption

Company Drug

BRL Medicine’s Allogeneic CD19 CAR‑T Included in CDE’s “Care Program‑Extension” – Rare Disease Fast Track for Relapsed/Refractory Systemic Sclerosis

Company Drug

Walvax’s Third‑Generation COVID‑19 mRNA Vaccine Wins NMPA Approval – JN.1‑Based Shot Clears Regulatory Bar for Adults in China

Policy / Regulatory

China’s Seventh National VBP Round for Medical Consumables Concludes in Tianjin – 517 Digestive Intervention Products Selected Across 23 Categories

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

© 2026 Fineline Information & Technology. Independent intelligence on China's pharmaceutical industry. Not investment advice. | BlogData by Themeansar.